Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q5VTD9
UPID:
GFI1B_HUMAN
Alternative names:
Growth factor independent protein 1B; Potential regulator of CDKN1A translocated in CML
Alternative UPACC:
Q5VTD9; O95270; Q5VTD8; Q6FHZ2; Q6T888
Background:
Zinc finger protein Gfi-1b, also known as Growth factor independent protein 1B, plays a pivotal role in the development and differentiation of erythroid and megakaryocytic lineages. It functions as a transcriptional regulator, influencing the expression of genes involved in hematopoietic differentiation and blood cell development. Gfi-1b's ability to bind to gamma-satellite DNA and auto-repress its expression showcases its complex regulatory mechanisms.
Therapeutic significance:
Gfi-1b's involvement in Bleeding disorder, platelet-type, 17, highlights its clinical relevance. This disorder, characterized by platelet dysfunction and abnormal bleeding, underscores the therapeutic potential of targeting Gfi-1b. Understanding the role of Gfi-1b could open doors to potential therapeutic strategies for managing bleeding disorders and improving platelet function.